JO3566B1 - تركيبات عامل تمايز النمو 15 (gdf15) - Google Patents

تركيبات عامل تمايز النمو 15 (gdf15)

Info

Publication number
JO3566B1
JO3566B1 JOP/2014/0240A JOP20140240A JO3566B1 JO 3566 B1 JO3566 B1 JO 3566B1 JO P20140240 A JOP20140240 A JO P20140240A JO 3566 B1 JO3566 B1 JO 3566B1
Authority
JO
Jordan
Prior art keywords
constructs
gdf
differentiation factor
growth differentiation
gdf15
Prior art date
Application number
JOP/2014/0240A
Other languages
English (en)
Inventor
Z Sheng Jackie
Kannan Gunasekaran
Walker Kenneth
Wang Zhulun
Xiong Yumei
Shimamoto Grant
Mock Marissa
VENIANT?ELLISON Murielle
Eva Hamburger Agnes
Tang Jie
Zhang Yi
Min Xiaoshan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51358091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3566(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of JO3566B1 publication Critical patent/JO3566B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<span dir="RTL">يتم تقديم تركيبات تتضمن </span>GDF15<span dir="RTL">، ومطفرات منه. في نماذج مختلفة يمكن إستخدام التركيبات التي تتضمن </span>GDF15<span dir="RTL">، ومطفرات منه، للإستخدام في علاج أو تحسين إضطراب أيضي. في نماذج مختلفة يكون المرض أو الإضطراب الأيضي عبارة عن مرض السكري من النوع 2، السمنة، إضطراب نسبة الدهون بالدم، ارتفاع مستويات الجلوكوز بالدم، إرتفاع نسبة الأنسولين بالدم، وإعتلال الكلى السكري</span>
JOP/2014/0240A 2013-07-31 2014-08-03 تركيبات عامل تمايز النمو 15 (gdf15) JO3566B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361860723P 2013-07-31 2013-07-31

Publications (1)

Publication Number Publication Date
JO3566B1 true JO3566B1 (ar) 2020-07-05

Family

ID=51358091

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0240A JO3566B1 (ar) 2013-07-31 2014-08-03 تركيبات عامل تمايز النمو 15 (gdf15)

Country Status (35)

Country Link
US (3) US9862752B2 (ar)
EP (2) EP3763734A1 (ar)
JP (4) JP6509852B2 (ar)
KR (3) KR102376451B1 (ar)
CN (2) CN113527512A (ar)
AP (1) AP2016009011A0 (ar)
AR (1) AR097181A1 (ar)
AU (1) AU2014296107B2 (ar)
BR (1) BR112016002213A2 (ar)
CA (1) CA2918624C (ar)
CL (1) CL2016000249A1 (ar)
CR (1) CR20160097A (ar)
CY (1) CY1123836T1 (ar)
DK (1) DK3027642T3 (ar)
EA (2) EA202092386A1 (ar)
ES (1) ES2828670T3 (ar)
HK (1) HK1225738A1 (ar)
HU (1) HUE050630T2 (ar)
IL (1) IL243749B (ar)
JO (1) JO3566B1 (ar)
LT (1) LT3027642T (ar)
MA (1) MA38873B1 (ar)
MX (2) MX369152B (ar)
NZ (2) NZ754961A (ar)
PE (1) PE20160189A1 (ar)
PH (1) PH12016500208B1 (ar)
PL (1) PL3027642T3 (ar)
PT (1) PT3027642T (ar)
SG (1) SG11201600713RA (ar)
SI (1) SI3027642T1 (ar)
TN (1) TN2016000035A1 (ar)
TW (1) TWI648401B (ar)
UA (1) UA116665C2 (ar)
UY (1) UY35686A (ar)
WO (1) WO2015017710A1 (ar)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2013113008A1 (en) * 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
JP6272907B2 (ja) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
MA38873B1 (fr) 2013-07-31 2018-11-30 Amgen Inc Constructions contenant le facteur 15 de différentiation de croissance (gdf-15)
JP2015182969A (ja) * 2014-03-21 2015-10-22 四国化成工業株式会社 トリアゾールシラン化合物、該化合物の合成方法及びその利用
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US9272019B2 (en) 2014-06-24 2016-03-01 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
SG11201700378PA (en) 2014-07-30 2017-02-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP3393494A1 (en) 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
IL261666B2 (en) 2016-03-31 2024-09-01 Ngm Biopharmaceuticals Inc Related proteins and methods of using them
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
WO2017202936A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and use thereof
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
KR102010652B1 (ko) * 2017-08-21 2019-08-13 서울대학교병원 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법
JP2020533302A (ja) 2017-09-10 2020-11-19 ノヴォ ノルディスク アー／エス 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CN111954537A (zh) 2018-04-09 2020-11-17 美国安进公司 生长分化因子15融合蛋白
TW202019518A (zh) * 2018-07-13 2020-06-01 丹麥商珍美寶股份有限公司 Ｃｄ３８抗體之變體及其用途
CR20210193A (es) 2018-10-22 2021-06-15 Janssen Pharmaceutica Nv Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas
EP3978518A4 (en) * 2019-04-23 2022-11-02 Lg Chem, Ltd. FUSION POLYPEPTIDE COMPRISING FC REGION OF IMMUNOGLOBULIN AND GDF15
TW202110877A (zh) 2019-05-30 2021-03-16 美商安進公司 工程改造鉸鏈區以驅動抗體二聚化
CA3142165A1 (en) 2019-06-07 2020-12-10 Amgen Inc. Bispecific binding constructs with selectively cleavable linkers
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
WO2021107603A2 (en) * 2019-11-26 2021-06-03 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
AU2020400805B2 (en) * 2019-12-11 2024-03-28 Lg Chem, Ltd. Fusion polypeptide comprising GDF15 and polypeptide region capable of O-glycosylation
EP4081536A1 (en) 2019-12-23 2022-11-02 Denali Therapeutics Inc. Progranulin variants
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
EP4237438A1 (en) 2020-10-27 2023-09-06 Beijing QL Biopharmaceutical Co., Ltd. Fusion proteins of gdf15 and use thereof
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023025120A1 (en) * 2021-08-24 2023-03-02 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and uses thereof
TW202342014A (zh) 2022-02-10 2023-11-01 瑞士商諾華公司 １，３－苯并二氧戊環衍生物
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN114835810B (zh) * 2022-03-31 2024-01-05 浙江特瑞思药业股份有限公司 一种抗pd-1纳米抗体及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
CA2356401A1 (en) * 1999-01-07 2000-07-13 Lexigen Pharmaceuticals, Corp. Expression and export of anti-obesity proteins as fc fusion proteins
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
KR20080085082A (ko) 2000-12-07 2008-09-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 융합 단백질
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
EP1395605B8 (en) 2001-03-09 2014-12-17 Iterative Therapeutics, Inc. Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors
JP4422949B2 (ja) 2001-06-26 2010-03-03 武田薬品工業株式会社 ＴＧＦ−βスーパーファミリー産生・分泌促進剤
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7101852B2 (en) 2003-05-30 2006-09-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment and prevention of restenosis
CN1829532A (zh) * 2003-06-02 2006-09-06 惠氏公司 肌肉抑制素（gdf8）抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2005047334A1 (en) * 2003-11-13 2005-05-26 Hanmi Pharmaceutical. Co., Ltd. Igg fc fragment for a drug carrier and method for the preparation thereof
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
WO2005099746A1 (en) 2004-04-13 2005-10-27 St Vincent's Hospital Sydney Limited Method for modulating appetite
US20090042780A1 (en) * 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
AU2005272646A1 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
BRPI0618488A2 (pt) * 2005-11-10 2011-08-30 Receptor Biologix Inc proteìnas de fusão de ìntron de fator de crescimento de hepatócito
CN1974601A (zh) * 2005-11-28 2007-06-06 上海新生源医药研究有限公司 一种新型Fc融合蛋白及其生产方法
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CA2694863A1 (en) 2007-08-16 2009-02-19 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
EP2279419A1 (en) 2008-05-20 2011-02-02 Roche Diagnostics GmbH Gdf-15 as biomarker in type 1 diabetes
WO2010017198A2 (en) 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
EP2350669B9 (en) * 2008-10-31 2014-06-11 St Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
MX340971B (es) 2009-11-23 2016-08-02 Amgen Inc * Fragmento cristalizable (fc) de anticuerpo monomerico.
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
MX2012006397A (es) * 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
US8772343B2 (en) 2010-07-12 2014-07-08 Pfizer Limited Chemical compounds
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
JP2013531030A (ja) 2010-07-12 2013-08-01 ファイザー・リミテッド 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド
ES2534921T3 (es) 2010-08-26 2015-04-30 F. Hoffmann-La Roche Ag Uso de biomarcadores en la evaluación de la transición temprana de la hipertensión arterial a la insuficiencia cardíaca
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
RS59589B1 (sr) * 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
JP5972915B2 (ja) 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
PL2697257T3 (pl) * 2011-04-13 2017-04-28 Bristol-Myers Squibb Company Białka fuzyjne fc o nowatorskim układzie lub zawierające nowatorskie łączniki
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
SI2794905T1 (sl) * 2011-12-20 2020-08-31 Medimmune, Llc Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
WO2013113008A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
EP2830646B1 (en) * 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2013249985B2 (en) * 2012-04-20 2017-11-23 Merus N.V. Methods and means for the production of Ig-like molecules
EA038645B1 (ru) 2012-12-21 2021-09-28 Авео Фармасьютикалз, Инк. Антитела к gdf15
JP6272907B2 (ja) * 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
MA38873B1 (fr) * 2013-07-31 2018-11-30 Amgen Inc Constructions contenant le facteur 15 de différentiation de croissance (gdf-15)
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
EP3157942B1 (en) 2014-06-23 2020-06-17 Novartis AG Site specific protein modifications
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US9272019B2 (en) 2014-06-24 2016-03-01 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
EP3393494A1 (en) 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
WO2017202936A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and use thereof
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法

Also Published As

Publication number Publication date
CR20160097A (es) 2016-07-29
NZ717030A (en) 2022-04-29
ES2828670T3 (es) 2021-05-27
HUE050630T2 (hu) 2020-12-28
US20210079051A1 (en) 2021-03-18
TWI648401B (zh) 2019-01-21
US20180079790A1 (en) 2018-03-22
CL2016000249A1 (es) 2016-07-22
JP2019178132A (ja) 2019-10-17
EA201690297A1 (ru) 2016-06-30
IL243749B (en) 2018-06-28
NZ754961A (en) 2022-04-29
US20160168213A1 (en) 2016-06-16
TW201602345A (zh) 2016-01-16
TN2016000035A1 (en) 2017-07-05
CA2918624A1 (en) 2015-02-05
HK1225738A1 (zh) 2017-09-15
KR20240000642A (ko) 2024-01-02
MX2019012848A (es) 2019-11-28
EA037355B1 (ru) 2021-03-17
PH12016500208A1 (en) 2016-04-25
EP3027642B1 (en) 2020-08-19
KR20160038896A (ko) 2016-04-07
UY35686A (es) 2015-01-30
CA2918624C (en) 2024-02-13
AP2016009011A0 (en) 2016-01-31
CN113527512A (zh) 2021-10-22
EP3027642A1 (en) 2016-06-08
PT3027642T (pt) 2020-10-30
MX2016001164A (es) 2016-07-26
PL3027642T3 (pl) 2021-01-11
AU2014296107B2 (en) 2018-07-26
AR097181A1 (es) 2016-02-24
JP2021113219A (ja) 2021-08-05
EA202092386A1 (ru) 2021-04-30
PH12016500208B1 (en) 2016-04-25
US9862752B2 (en) 2018-01-09
US10894814B2 (en) 2021-01-19
AU2014296107A1 (en) 2016-02-04
BR112016002213A2 (pt) 2017-08-29
JP6877478B2 (ja) 2021-05-26
KR102616674B1 (ko) 2023-12-29
MA38873A1 (fr) 2017-09-29
SI3027642T1 (sl) 2020-11-30
KR102376451B1 (ko) 2022-03-23
MA38873B1 (fr) 2018-11-30
MX369152B (es) 2019-10-30
CY1123836T1 (el) 2022-03-24
EP3763734A1 (en) 2021-01-13
KR20220038829A (ko) 2022-03-29
LT3027642T (lt) 2020-10-12
JP2023116723A (ja) 2023-08-22
PE20160189A1 (es) 2016-05-06
UA116665C2 (uk) 2018-04-25
IL243749A0 (en) 2016-04-21
DK3027642T3 (da) 2020-11-02
WO2015017710A1 (en) 2015-02-05
JP6509852B2 (ja) 2019-05-08
CN105980400B (zh) 2021-05-07
JP2016532690A (ja) 2016-10-20
CN105980400A (zh) 2016-09-28
SG11201600713RA (en) 2016-02-26

Similar Documents

Publication Publication Date Title
MX2019012848A (es) Construcciones del factor de diferenciacion de crecimiento 15 (gdf-15).
EP3683228A3 (en) Growth differentiation factor 15 (gdf-15) polypeptides
MX343729B (es) Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos.
JOP20200202A1 (ar) اجسام مضادة بشرية لمستقبل الجلوكاجون
WO2013033452A3 (en) Fgf21 for use in treating type 1 diabetes
NZ596037A (en) Fgf21 mutants and uses thereof
IN2015DN00397A (ar)
MX2015008114A (es) Derivados de exendina-4.
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
MX347372B (es) Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
WO2012174534A3 (en) Method of treating or ameliorating metabolic disorders using clec-2
WO2014014819A3 (en) Methods of treating glucose metabolism disorders
PH12015502068A1 (en) Treatment of insulin resistance associated with prolonged physical inactivity
Miyamoto CLINICAL APPLICATION OF ELECTRICAL MUSCLE STIMULATION FOR TYPE 2 DIABETES WITH EXERCISE INTOLERANCE
Ikeda Estimation of basal energy expenditure in patients with diabetes
Kim Importance of Quality of Life in Pain Management for Cancer Patients
TH168762A (th) สิ่งที่สร้างขึ้นเป็นโกรทดิฟเฟอเรนชิเอชันแฟคเตอร์ 15 (gdf-15)
TN2016000064A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
UA79751U (ru) Способ прогнозирования течения заболевания у больных с первично-локализованной меланомой кожи
UA82795U (ru) Способ оценки влияния электромагнитных излучений персональных компьютеров и мобильных телефонов на организм человека
UA76568U (ru) Лечебно-столовая вода для лечения онкологических патологий, сахарного диабета, сердечно-сосудистых патологий, патологий кожи и снижения веса пациентов с избыточным весом
MX2008001011A (es) Formulación auxiliar para el control de niveles altos de glucosa en sangre (hiperglicemia).